Lantern Pharma Inc.
LTRN
$3.59
-$0.03-0.83%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -40.36% | -42.52% | -4.49% | -40.67% | -23.80% |
| Total Depreciation and Amortization | -68.82% | 1,194.59% | 1,222.86% | 1,226.47% | 16.45% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 321.86% | -164.47% | -94.87% | -43.51% | -227.24% |
| Change in Net Operating Assets | 49.37% | -17.19% | -144.39% | 986.36% | 131.19% |
| Cash from Operations | -17.32% | -54.54% | -44.51% | 18.33% | -26.85% |
| Capital Expenditure | 39.22% | 37.50% | -- | 75.28% | 27.14% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 1,220.44% | 188.96% | 56.74% | 41.81% | -57.15% |
| Cash from Investing | 1,245.55% | 193.61% | 55.80% | 42.12% | -57.51% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 100.00% | -- | -- | -- | -- |
| Foreign Exchange rate Adjustments | -1,300.00% | 232.79% | 276.56% | -96.00% | -148.48% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 83.72% | -43.66% | -32.69% | 24.20% | -76.74% |